Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
- 1 February 2009
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 373 (9664), 641-648
- https://doi.org/10.1016/s0140-6736(09)60402-5
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Self‐reported health‐related quality of life in adults with chronic immune thrombocytopenic purpuraAmerican Journal of Hematology, 2007
- New thrombopoietic growth factorsBlood, 2007
- Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonistBlood, 2007
- Novel Thrombopoietic AgentsHematology, 2007
- An open‐label, unit dose‐finding study of AMG 531, a novel thrombopoiesis‐stimulating peptibody, in patients with immune thrombocytopenic purpuraBritish Journal of Haematology, 2006
- Management of Immune Thrombocytopenic Purpura in AdultsMayo Clinic Proceedings, 2004
- Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpuraBlood, 2004
- Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitroBlood, 2003
- Interpretation of Changes in Health-related Quality of LifeMedical Care, 2003
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986